Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

2.5. Definition of study end points

JK J.D. Katz
AB A.J. Bouley
RJ R.M. Jungquist
ED E.A. Douglas
IO I.L. O'Shea
EL E.S. Lathi
ask Ask a question
Favorite

The primary endpoint of this study was the production of SARS-CoV-2 spike protein antibodies 4 weeks after completion of vaccination. Antibody test results were defined as either positive (≥0.80 U/mL) or negative (<0.80 U/mL) as per the manufacturer's guidelines.

The presence of SARS-CoV-2 specific T-cells was assessed in OCR-treated patients with a negative antibody response after vaccination. Demographic and clinical factors including weight, BMI, age, race, baseline level of disability, MS disease subtype, duration of disease, duration of treatment, time from prior relapse, and smoking status were assessed as potential predictors of vaccine response.

Copyright and License information:  ©2021 The Authors
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A